VERACYTE, INC. — Investor Relations & Filings

Veracyte is a global diagnostics company that develops and commercializes genomic tests to transform cancer care. The company provides clinicians with high-value, actionable insights to guide patient management at pivotal moments, such as determining the need for surgery or selecting optimal therapies. Its portfolio of molecular diagnostic tests, including the Afirma Thyroid Genomic Sequencing Classifier and the Decipher Prostate portfolio, addresses key clinical questions across various types of cancer. Veracyte leverages its proprietary Veracyte Diagnostics Platform, which combines broad genomic assays with AI-assisted data analysis, to generate robust clinical evidence and develop innovative tests. The company aims to expand global access to its diagnostics through both centralized laboratories and distributed in-vitro diagnostic (IVD) kits.